Background: Colorectal cancer is a devastating disease with a dismal prognosis which is
heavily hampered by delayed diagnosis. Surgical resection, radiation therapy and chemotherapy are the
curative options. Due to few therapeutic treatments available i.e., mono and combination therapy and
development of resistance towards drug response, novel and efficacious therapy are urgently needed.
Objective: In this study, we have studied the potential of histone deacetylase inhibitors in colorectal cancer.
Results: Histone deacetylase inhibitors (HDACIs) are an emerging class of therapeutic agents having
potential anticancer activity with minimal toxicity for different types of malignancies in preclinical
studies. HDACIs have proven less effective in monotherapy thus the combination of HDACIs with
other anticancer agents are being assessed for the treatment of colorectal cancer.
Conclusion: The molecular mechanism emphasizing the anticancer effect of HDACIs in colorectal
cancer was illustrated and a recapitulation was carried out on the recent advances in the rationale behind
combination therapies currently underway in clinical evaluations.